Diagonal Bio is a dynamic and innovative company that develops a groundbreaking platform technology for ultra-fast, easy-to-use, and accurate detection of genetic markers. The company was founded at the onset of the covid-19 pandemic in 2020 with the express goal to revolutionise diagnosis of infectious diseases. Diagonal Bio’s team is led by experienced professionals in the biotechnology field, including COB Kerstin Jakobsson, interim CEO Karin Wehlin, CFO Per Heander, and a diverse board of directors. Diagonal's operations are based in Lund, Sweden and its scientific advisors include Prof. Vicent Pelechano (Karolinska Institute, Sweden), Prof. Christelle Prinz (Lund University, Sweden), Prof. Patrik Medstrand (Lund University), Prof. Tautgirdas Ruzgas (Malmö University, Sweden) and Kushagr Punyani (Spermosens AB). www.diagonalbio.com